Original Articles

You have full text access to this OnlineOpen article

Early high peak hepatitis C viral load levels independently predict hepatitis C–related liver failure post–liver transplantation

  1. Nicholas A. Shackel1,2,3,†,‡,*,
  2. Jade Jamias1,3,†,
  3. Wassim Rahman1,3,
  4. Emilia Prakoso1,2,3,
  5. Simone I. Strasser1,3,
  6. David J. Koorey1,3,
  7. Michael D. Crawford1,
  8. Deborah J. Verran1,
  9. James Gallagher1,
  10. Geoffrey W. McCaughan1,2,3

Article first published online: 26 JUN 2009

DOI: 10.1002/lt.21747

Issue

Liver Transplantation

Liver Transplantation

Volume 15, Issue 7, pages 709–718, July 2009

Additional Information

How to Cite

Shackel, N. A., Jamias, J., Rahman, W., Prakoso, E., Strasser, S. I., Koorey, D. J., Crawford, M. D., Verran, D. J., Gallagher, J. and McCaughan, G. W. (2009), Early high peak hepatitis C viral load levels independently predict hepatitis C–related liver failure post–liver transplantation. Liver Transpl, 15: 709–718. doi: 10.1002/lt.21747

Author Information

  1. 1

    A.W. Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia

  2. 2

    Centenary Institute of Cancer Medicine and Cell Biology, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia

  3. 3

    Centre for Clinical Research Excellence To Improve Outcomes in Chronic Liver Disease, University of Sydney, Sydney, Australia

  1. †

    These authors contributed equally to this study.

  2. ‡

    Telephone: +1 61 2 95656286; FAX: +61 2 95656101

*Royal Prince Alfred Hospital, Locked Bag No. 6, Newtown, Sydney, New South Wales, Australia 2050

Publication History

  1. Issue published online: 26 JUN 2009
  2. Article first published online: 26 JUN 2009
  3. Manuscript Accepted: 29 DEC 2008
  4. Manuscript Received: 25 AUG 2008

Funded by

  • National Health and Medical Research Council Clinical Center of Research Excellence Grant. Grant Number: 219282
  • Roche CellCept Australia Research Grant

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (268K)

REFERENCES

  • 1
    He XS, Rehermann B, Lopez Labrador FX, Boisvert J, Cheung R, Mumm J, et al. Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci U S A 1999; 96: 5692–5697.
  • 2
    Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889–896.
  • 3
    Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823–830.
    Direct Link:
  • 4
    Rosen HR, Gretch DR, Oehlke M, Flora KD, Benner KG, Rabkin JM, Corless CL. Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury. Transplantation 1998; 65: 1178–1182.
  • 5
    Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997; 92: 1453–1457.
  • 6
    Hoofnagle JH, Lombardero M, Zetterman RK, Lake J, Porayko M, Everhart J, et al. Donor age and outcome of liver transplantation. Hepatology 1996; 24: 89–96.
    Direct Link:
  • 7
    Bierer BE, Burakoff SJ. T-cell adhesion molecules. FASEB J 1988; 2: 2584–2590.
  • 8
    Rustgi SD, Marino G, Halpern MT, Umana WO, Tolleris C, Rustgi VK. Impact of donor age on graft survival among liver transplant recipients: analysis of the United Network for Organ Sharing database. Transplant Proc 2002; 34: 3295–3297.
  • 9
    Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002; 51: 248–252.
  • 10
    Sreekumar R, Rosado B, Rasmussen D, Charlton M. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology 2003; 38: 244–251.
    Direct Link:
  • 11
    Feray C, Caccamo L, Alexander GJ, Ducot B, Gugenheim J, Casanovas T, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999; 117: 619–625.
  • 12
    Everhart JE, Wei Y, Eng H, Charlton MR, Persing DH, Wiesner RH, et al. Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology 1999; 29: 1220–1226.
    Direct Link:
  • 13
    Zekry A, Whiting P, Crawford DH, Angus PW, Jeffrey GP, Padbury RT, et al. Liver transplantation for HCV-associated liver cirrhosis: predictors of outcomes in a population with significant genotype 3 and 4 distribution. Liver Transpl 2003; 9: 339–347.
    Direct Link:
  • 14
    McCormick SE, Goodman ZD, Maydonovitch CL, Sjogren MH. Evaluation of liver histology, ALT elevation, and HCV RNA titer in patients with chronic hepatitis C. Am J Gastroenterol 1996; 91: 1516–1522.
  • 15
    Lau JY, Wright TL. Molecular virology and pathogenesis of hepatitis B. Lancet 1993; 342: 1335–1340.
  • 16
    Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C. Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Ann Intern Med 1995; 122: 161–168.
  • 17
    Di Martino V, Saurini F, Samuel D, Gigou M, Dussaix E, Reynes M, et al. Long-term longitudinal study of intrahepatic hepatitis C virus replication after liver transplantation. Hepatology 1997; 26: 1343–1350.
    Direct Link:
  • 18
    Papatheodoridis GV, Barton SG, Andrew D, Clewley G, Davies S, Dhillon AP, et al. Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: the role of different immunosuppressive regimens. Gut 1999; 45: 427–434.
  • 19
    Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815–820.
  • 20
    Chazouilleres O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998; 28: 296–301.
    Direct Link:
  • 21
    Hamada K, Takuwa N, Zhou W, Kumada M, Takuwa Y. Protein kinase C inhibits the CAK-CDK2 cyclin-dependent kinase cascade and G1/S cell cycle progression in human diploid fibroblasts. Biochim Biophys Acta 1996; 1310: 149–156.
  • 22
    Duvoux C, Pawlotsky JM, Cherqui D, Tran van Nhieu J, Metreau JM, Fagniez PL, et al. Serial quantitative determination of hepatitis C virus RNA levels after liver transplantation. A useful test for diagnosis of hepatitis C virus reinfection. Transplantation 1995; 60: 457–461.
  • 23
    Doughty AL, Spencer JD, Cossart YE, McCaughan GW. Cholestatic hepatitis after liver transplantation is associated with persistently high serum hepatitis C virus RNA levels. Liver Transpl Surg 1998; 4: 15–21.
    Direct Link:
  • 24
    Burroughs AK. Induction immunosuppression for patients who underwent transplantation for cirrhosis caused by hepatitis C? The answer is no! Liver Transpl 2002; 8: S47–S49.
    Direct Link:
  • 25
    Northup PG, Chong TW, Iezzoni JC, Kerr SE, Burns AS, Pruett TL. Tacrolimus versus cyclosporine based immunosuppression in hepatitis C patients after liver transplantation: long-term follow-up of a randomized controlled trial. In: Program and abstracts of the 57th Annual Meeting of the American Association for the Study of Liver Diseases; October 27–31, 2006; Boston, MA. Abstract 602 2006.
  • 26
    Martin P, Busuttil RW, Goldstein RM, Crippin JS, Klintmalm GB, Fitzsimmons WE, Uleman C. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl 2004; 10: 1258–1262.
    Direct Link:
  • 27
    Levy G, Villamil F, Samuel D, Sanjuan F, Grazi GL, Wu Y, et al. Results of LIS2T, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 2004; 77: 1632–1638.
  • 28
    Fisher RA, Stone JJ, Wolfe LG, Rodgers CM, Anderson ML, Sterling RK, et al. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation. Clin Transplant 2004; 18: 463–472.
    Direct Link:
  • 29
    Baugh LR, Hill AA, Brown EL, Hunter CP. Quantitative analysis of mRNA amplification by in vitro transcription. Nucleic Acids Res 2001; 29: E29.
  • 30
    Stangl JR, Carroll KL, Illichmann M, Striker R. Effect of antimetabolite immunosuppressants on Flaviviridae, including hepatitis C virus. Transplantation 2004; 77: 562–567.
  • 31
    Gane EJ, Naoumov NV, Qian KP, Mondelli MU, Maertens G, Portmann BC, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110: 167–177.
  • 32
    Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N, Kishikawa K, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21: 30–34.
    Direct Link:
  • 33
    Escribano L, Diaz-Agustin B, Lopez A, Nunez Lopez R, Garcia-Montero A, Almeida J, et al. Immunophenotypic analysis of mast cells in mastocytosis: when and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA). Cytometry B Clin Cytom 2004; 58: 1–8.
    Direct Link:
  • 34
    Papatheodoridis GV, Davies S, Dhillon AP, Teixeira R, Goulis J, Davidson B, et al. The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosis. Transplantation 2001; 72: 412–418.
View Full Article (HTML) Get PDF (268K)